Defining the Natural History of Squamous Cell Carcinoma in Fanconi Anemia

Key facts

Sponsor

National Cancer Institute (NCI)

Principal Investigator

Lisa J McReynolds, M.D.

National Cancer Institute (NCI)

Enrollment

200 enrolled

Eligibility

8-90 years · All sexes

Timeline

2023 – 2035

Study locations (1)

• National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Fanconi anemia

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT06744283
  Experience and Management of Cancer Screening-Related Anxiety in Fanconi Anemia
  National Cancer Institute (NCI)
• RECRUITINGPHASE1, PHASE2NCT06648096
  Afatinib in Patients with Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
  Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
• RECRUITINGNANCT05973656
  Role of Acetaldehyde in the Development of Oral Cancer
  Masonic Cancer Center, University of Minnesota
• RECRUITINGPHASE1, PHASE2NCT04784052
  Depleted Donor Stem Cell Transplant in Children and Adults With Fanconi Anemia After Being Conditioned With a Regimen Containing Briquilimab
  Porteus, Matthew, MD
• ACTIVE NOT RECRUITINGPHASE2NCT04248439
  Gene Therapy for Fanconi Anemia, Complementation Group A
  Rocket Pharmaceuticals Inc.
• ACTIVE NOT RECRUITINGNANCT04437771
  Long-Term Follow-up of Subjects With Fanconi Anaemia Subtype A Treated With ex Vivo Gene Therapy
  Rocket Pharmaceuticals Inc.
• ACTIVE NOT RECRUITINGPHASE2NCT04069533
  Lentiviral-mediated Gene Therapy for Pediatric Patients With Fanconi Anemia Subtype A
  Rocket Pharmaceuticals Inc.
• RECRUITINGPHASE2NCT03579875
  Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders
  Masonic Cancer Center, University of Minnesota

See all trials for Fanconi anemia →